PET tracers for imaging of ABC transporters at the blood-brain barrier: Principles and Strategies

Gert Luurtsema*, Philip Elsinga, Rudi Dierckx, Ronald Boellaard, Aren van Waarde

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

20 Citaten (Scopus)


ABC transporters at the human blood-brain barrier protect the brain against the entry of harmful compounds but may also limit (or prevent) the cerebral entry of therapeutic drugs (e.g. anti-epileptics, antidepressants and antipsychotics). The efflux function of these transporters may be impaired in neurodegenerative disorders like Alzheimer and Parkinson disease. For such reasons, there is much interest in modulation of the efflux function of ABC transporters and in the monitoring of this function with positron emission tomography (PET). The efflux function of P-glycoprotein, an important member of the ABC transporter family, can be quantified with the PET tracer (R)-[C-11] verapamil, but the lipophilicity of this probe and the formation of radioactive metabolites which enter the brain complicate such measurements considerably. (R)-[C-11] verapamil is also not very suitable for the detection of P-gp upregulation, as may occur in epilepsy or drug resistance. Current radiochemical efforts are therefore focused on the development of PET probes with improved characteristics, for example; capability to detect both up-and down regulation of transporter function and expression, a better metabolic profile (no brain-entering metabolites), reduced lipophilicity and a longer physical half-life (labeling with F-18 instead of C-11).

Originele taal-2English
Pagina's (van-tot)5779-5785
Aantal pagina's7
TijdschriftCurrent Pharmaceutical Design
Nummer van het tijdschrift38
StatusPublished - 10-aug-2016

Citeer dit